Abstract
Second-generation antipsychotics have been growingly implicated in the acute and maintenance treatment for bipolar affective disorder (BAD). Risperidone long-acting injection (LAI) has been the first second-generation depot indicated for its maintenance treatment. However, its long-term motor side-effects, especially tardive dyskinesia (TD), has not been commonly reported or studied. The case reported here a bipolar patient with atypical presentation of TD involving only the crico-hyoid region of the neck associated with the use of risperidone LAI in adjunct to lithium and sodium valproate as maintenance therapy.
Keywords: Risperidone long-acting injection, bipolar, maintenance, tardive dyskinesia, crico-hyoid region
Current Drug Safety
Title:Atypical Presentation of Tardive Dyskinesia Associated with Risperidone Long-Acting Injection as Maintenance Treatment in Bipolar Affective Disorder: A Case Report
Volume: 7 Issue: 1
Author(s): Albert K.K. Chung
Affiliation:
Keywords: Risperidone long-acting injection, bipolar, maintenance, tardive dyskinesia, crico-hyoid region
Abstract: Second-generation antipsychotics have been growingly implicated in the acute and maintenance treatment for bipolar affective disorder (BAD). Risperidone long-acting injection (LAI) has been the first second-generation depot indicated for its maintenance treatment. However, its long-term motor side-effects, especially tardive dyskinesia (TD), has not been commonly reported or studied. The case reported here a bipolar patient with atypical presentation of TD involving only the crico-hyoid region of the neck associated with the use of risperidone LAI in adjunct to lithium and sodium valproate as maintenance therapy.
Export Options
About this article
Cite this article as:
K.K. Chung Albert, Atypical Presentation of Tardive Dyskinesia Associated with Risperidone Long-Acting Injection as Maintenance Treatment in Bipolar Affective Disorder: A Case Report, Current Drug Safety 2012; 7 (1) . https://dx.doi.org/10.2174/157488612800492807
DOI https://dx.doi.org/10.2174/157488612800492807 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Insight into the Therapeutic Role of 5-HT1A Receptors in Central Nervous System Disorders
Central Nervous System Agents in Medicinal Chemistry Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry
Current Neuropharmacology Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Gene Therapy for Parkinsons Disease: Progress and Challenges
Current Gene Therapy Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities
Current Pharmaceutical Biotechnology Genotyping as a Tool to Predict Adverse Drug Reactions
Current Topics in Medicinal Chemistry The Modulation of Pain by Metabotropic Glutamate Receptors 7 and 8 in the Dorsal Striatum
Current Neuropharmacology Is a "Mitochondrial Psychiatry" in the Future? A Review
Current Psychiatry Reviews Deprescribing for Psychiatry: The Right Prescription?
Current Psychiatry Reviews Flavonoids and the Brain: Evidences and Putative Mechanisms for a Protective Capacity
Current Neuropharmacology Revisiting the Medical Management of Parkinson’s Disease: Levodopa versus Dopamine Agonist
Current Neuropharmacology Clozapine Safety, 40 Years Later
Current Drug Safety Molecular Effects of L-dopa Therapy in Parkinson’s Disease
Current Genomics The Endocannabinoid System in Parkinsons Disease
Current Pharmaceutical Design AtreMorine Treatment Regulates DNA Methylation in Neurodegenerative Disorders: Epigenetic and Pharmacogenetic Studies
Current Pharmacogenomics and Personalized Medicine Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Current Medicinal Chemistry Etiopathogenesis and Treatment of Parkinsons Disease
Current Topics in Medicinal Chemistry Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Trends and Applications of Brain Computer Interfaces
Current Signal Transduction Therapy Nitric Oxide in Health and Disease from the Point of View of the Otorhinolaryngologist
Current Pharmaceutical Design